A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation

被引:62
作者
Le Blanc, K [1 ]
Remberger, M [1 ]
Uzunel, M [1 ]
Mansson, J [1 ]
Barkholt, L [1 ]
Ringdén, O [1 ]
机构
[1] Huddinge Univ Hosp, Div Clin Immunol, Karolinska Inst, SE-14186 Stockholm, Sweden
关键词
allogeneic hematopoictic stem-cell transplantation; absolute neutrophil count; antithymocyte globulin; graft-versus-host disease; nonmyeloablative conditioning; reduced-intensity conditioning;
D O I
10.1097/01.TP.0000129809.09718.7E
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Nonmyeloablative (NM) conditioning and reduced-intensity conditioning (RIC) are increasingly used for allogeneic hernatopoietic stem-cell transplantation. Such regimens have not been compared. Methods. The primary endpoint was graft-versus-host disease (GVHD). Secondary endpoints included transfusions, engraftment, and transplant-related mortality (TRM). NM conditioning (n = 24) consisted of fludarabine and 2-Gy total-body irradiation followed by immunosuppression with cyclosporine A (CsA) combined with mycophenolate mofetil (MMF). The RIC (n = 34) protocol consisted of fludarabine combined with busulfan or cyclophosphamide, antithymocyte globulin, and posttransplant immunosuppression CsA plus methotrexate. Diagnoses included hematologic malignancies and solid tumors. Donors were 34 human leukocyte antigen-identical siblings and 24 unrelated donors. Chimerism was analyzed by polymerase chain reaction of minisatellites. Results. Graft failure occurred in 6 of 24 in the NM group and in I of 34 in the RIC group, which was a significant difference (odds ratio [OR], 22.6; P = 0.02). The NM group also had less leukopenia and required fewer erythrocyte and platelet transfusions than the RIC group. The time to and proportion of CD3, CD19, and CD45 donor chimerism were similar in both groups. The cumulative incidence of grades II to IV acute GVHD was higher in the NM group (59% vs. 12%; OR, 26.9; P < 0.001), but we found no difference in the cumulative incidence of chronic GVHD (41% vs. 61%). TRM was 42% in the NM group and 20% in the RIC patients (relative hazard, 11.6; P = 0.03). Conclusions. NM conditioning with posttransplant immunosuppression using CsA and MMF resulted in less leukopenia and fewer transfusions, but resulted in more cases of graft failure, acute GVHD, and TRM than in RIC patients.
引用
收藏
页码:1014 / 1020
页数:7
相关论文
共 30 条
[1]   Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation [J].
Bornhäuser, M ;
Schuler, U ;
Pörksen, G ;
Naumann, R ;
Geissler, G ;
Thiede, C ;
Schwerdtfeger, R ;
Ehninger, G ;
Thiede, HM .
TRANSPLANTATION, 1999, 67 (04) :499-504
[2]   Risk factors for chronic graft-versus-host disease after bone marrow transplantation:: a retrospective single centre analysis [J].
Carlens, S ;
Ringdén, O ;
Remberger, M ;
Lönnqvist, B ;
Hägglund, H ;
Klaesson, S ;
Mattsson, J ;
Svahn, BM ;
Winiarski, J ;
Ljungman, P ;
Aschan, J .
BONE MARROW TRANSPLANTATION, 1998, 22 (08) :755-761
[3]   Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia [J].
Carlens, S ;
Aschan, J ;
Remberger, M ;
Dilber, MS ;
Ringdén, O .
BONE MARROW TRANSPLANTATION, 1999, 24 (06) :629-635
[4]  
CUTLER C, 2003, BIOL BLOOD MARROW TR, V9, P76
[5]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[6]   A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation [J].
Hägglund, H ;
Ringdén, O ;
Öman, S ;
Remberger, M ;
Carlens, S ;
Mattsson, J .
BONE MARROW TRANSPLANTATION, 1999, 24 (08) :831-836
[7]   Reduced intensity conditioning regimens -: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma [J].
Hentschke, P ;
Barkholt, L ;
Uzunel, M ;
Mattsson, J ;
Wersäll, P ;
Pisa, P ;
Martola, J ;
Albiin, N ;
Wernerson, A ;
Söderberg, M ;
Remberger, M ;
Thörne, A ;
Ringdén, O .
BONE MARROW TRANSPLANTATION, 2003, 31 (04) :253-261
[8]  
HOROWITZ MM, 1990, BLOOD, V75, P555
[9]  
Ljungman P, 1996, BONE MARROW TRANSPL, V17, P583
[10]   Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects [J].
McSweeney, PA ;
Niederwieser, D ;
Shizuru, JA ;
Sandmaier, BM ;
Molina, AJ ;
Maloney, DG ;
Chauncey, TR ;
Gooley, TA ;
Hegenbart, U ;
Nash, RA ;
Radich, J ;
Wagner, JL ;
Minor, S ;
Appelbaum, FR ;
Bensinger, WI ;
Bryant, E ;
Flowers, MED ;
Georges, GE ;
Grumet, FC ;
Kiem, HP ;
Torok-Storb, B ;
Yu, G ;
Blume, KG ;
Storb, RF .
BLOOD, 2001, 97 (11) :3390-3400